Sustained anxiolytic and antidepressant effects of botulinum toxin A in blepharospasm patients beyond motor symptom control.
Abstract
[BACKGROUND] The previous studies have primarily focused on the influence of botulinum toxin A (BoNT-A) injection on emotions during the period of peak motor symptom improvement in blepharospasm patients, based on facial feedback hypothesis.
[AIM] To evaluate the sustained anxiolytic and antidepressant effects of BoNT-A in blepharospasm patients beyond motor symptom control.
[METHODS] We recruited benign essential blepharospasm patients with BoNT-A treatment and collected their data to compare scale scores of Jankovic Rating Scale, Blepharospasm Disability Index, Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), Hamilton Anxiety Scale and Hamilton Depression Scale between pre-treatment (baseline) and pre-reinjection (treatment), to further assess the effects of repeated treatments with BoNT by using sub-group analyses in the certain special states.
[RESULTS] A total of 21 eligible blepharospasm patients were with the mean age of 58.4 years and a male-to-female ratio of 1:6. Significantly decreases in the subscale scores of SDS and SAS, including SDS well-being index, decreased capacity and hard to decide, SAS inability to sit still and headache were showed at post-a single BoNT-A injection when scale scores of Jankovic Rating Scale and Blepharospasm Disability Index were matched between baseline and post-treatment. With each additional BoNT-A injection, the odds ratio of patients with the moderate depressive symptoms decreased by 92.6%. Moreover, BoNT treatment remained a decrease in the subscale scores of SDS and SAS in patients with repeated injections.
[CONCLUSION] This study is to demonstrate that repeated BoNT-A injection have a long-lasting relief for anxiety and depressive symptoms in blepharospasm even after its motor symptom-modulating effects have diminished.
[AIM] To evaluate the sustained anxiolytic and antidepressant effects of BoNT-A in blepharospasm patients beyond motor symptom control.
[METHODS] We recruited benign essential blepharospasm patients with BoNT-A treatment and collected their data to compare scale scores of Jankovic Rating Scale, Blepharospasm Disability Index, Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), Hamilton Anxiety Scale and Hamilton Depression Scale between pre-treatment (baseline) and pre-reinjection (treatment), to further assess the effects of repeated treatments with BoNT by using sub-group analyses in the certain special states.
[RESULTS] A total of 21 eligible blepharospasm patients were with the mean age of 58.4 years and a male-to-female ratio of 1:6. Significantly decreases in the subscale scores of SDS and SAS, including SDS well-being index, decreased capacity and hard to decide, SAS inability to sit still and headache were showed at post-a single BoNT-A injection when scale scores of Jankovic Rating Scale and Blepharospasm Disability Index were matched between baseline and post-treatment. With each additional BoNT-A injection, the odds ratio of patients with the moderate depressive symptoms decreased by 92.6%. Moreover, BoNT treatment remained a decrease in the subscale scores of SDS and SAS in patients with repeated injections.
[CONCLUSION] This study is to demonstrate that repeated BoNT-A injection have a long-lasting relief for anxiety and depressive symptoms in blepharospasm even after its motor symptom-modulating effects have diminished.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 약물 | antidepressant
|
C0003289
Antidepressive Agents
|
scispacy | 1 | |
| 약물 | botulinum toxin A
|
C0006050
botulinum toxin type A
|
scispacy | 1 | |
| 약물 | [BACKGROUND]
|
scispacy | 1 | ||
| 약물 | [RESULTS] A
|
scispacy | 1 | ||
| 약물 | BoNT-A
→ botulinum toxin A
|
scispacy | 1 | ||
| 약물 | BoNT
|
scispacy | 1 | ||
| 질환 | blepharospasm
|
C0005747
Blepharospasm
|
scispacy | 1 | |
| 질환 | Anxiety
|
C0003467
Anxiety
|
scispacy | 1 | |
| 질환 | Self-rating Depression
|
scispacy | 1 | ||
| 질환 | Depression
|
C0011570
Mental Depression
|
scispacy | 1 | |
| 질환 | headache
|
C0018681
Headache
|
scispacy | 1 | |
| 질환 | depressive symptoms
|
C0086132
Depressive Symptoms
|
scispacy | 1 | |
| 질환 | blepharospasm patients
|
scispacy | 1 | ||
| 기타 | botulinum toxin A
|
scispacy | 1 | ||
| 기타 | BoNT-A
→ botulinum toxin A
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | SAS
→ Self-rating Anxiety Scale
|
scispacy | 1 |
📑 인용 관계
이 논문이 참조한 문헌 42
- Depressive symptoms and quality of life in patients with benign essential blepharospasm under long-t…
- Botulinum Toxin Type A Exerts Direct Trans-Synaptic Action at Bilateral Spinal Nociceptive Circuits.
- The Face of Emotion: Botulinum Toxin, Emotional Anatomy, and Mood Modulation.
- Basis of movement control in dystonia and why botulinum toxin should influence it?
- Comparative effectiveness of two different doses of botulinum toxin A for the treatment of mild to m…
- Neurosurgical and pharmacological management of dystonia.
- Correlation between blepharospasm and psychological diseases: the anxiety, depression and sleep diso…
- Subject satisfaction and psychological well-being with escalating abobotulinumtoxinA injection dose …
- Treatment of Depression with Botulinum Toxin.
- Botulinum Toxin-A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches.
- Impact of botulinum toxin for facial aesthetics on psychological well-being and quality of life: Evi…
- THE EFFECT OF BOTULINUM TOXIN TYPE A IN PATIENTS WITH ESSENTIAL BLEPHAROSPASM.
- Which factors impact on quality of life for adults with blepharospasm and hemifacial spasm?
- Botulinum Toxin in Movement Disorders: An Update.
- Botulinum Toxin: An Update on Pharmacology and Newer Products in Development.
- Effects of Botulinum Toxin Type A on the Psychosocial Features of Myofascial Pain TMD Subjects: A Ra…
- Subjective assessment of effectiveness, quality of life, and psychological status of patients receiv…
- Evidence for central antispastic effect of botulinum toxin type A.
- Botulinum Toxin in the Treatment of Headache.
- Botulinum toxin type A therapy for blepharospasm.
외부 PMID 22건 (DB 미수집)
- PMID 1011031 ↗
- PMID 1156115 ↗
- PMID 13638508 ↗
- PMID 14221692 ↗
- PMID 14399272 ↗
- PMID 16198532 ↗
- PMID 16951564 ↗
- PMID 17394234 ↗
- PMID 17543569 ↗
- PMID 18385327 ↗
- PMID 18467364 ↗
- PMID 18485989 ↗
- PMID 18792121 ↗
- PMID 19264088 ↗
- PMID 20108377 ↗
- PMID 21431990 ↗
- PMID 24345483 ↗
- PMID 24910934 ↗
- PMID 25958249 ↗
- PMID 28186662 ↗
- PMID 28761348 ↗
- PMID 5172928 ↗
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.